ES2145978T3 - Intermedios y su uso para preparar bisindolilmaleimidas con un puente n,n'. - Google Patents

Intermedios y su uso para preparar bisindolilmaleimidas con un puente n,n'.

Info

Publication number
ES2145978T3
ES2145978T3 ES96308317T ES96308317T ES2145978T3 ES 2145978 T3 ES2145978 T3 ES 2145978T3 ES 96308317 T ES96308317 T ES 96308317T ES 96308317 T ES96308317 T ES 96308317T ES 2145978 T3 ES2145978 T3 ES 2145978T3
Authority
ES
Spain
Prior art keywords
prepare
intermediates
bridge
bisindolyl maleimides
bisindolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96308317T
Other languages
English (en)
Inventor
Margaret Mary Faul
Christine Ann Krumrich
Leonard Larry Winneroski Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21725638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2145978(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2145978T3 publication Critical patent/ES2145978T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA COMPUESTOS DE FORMULA: LA INVENCION PROPORCIONA ASIMISMO, LA UTILIZACION DE DICHOS COMPUESTOS PARA PREPARAR BISINDOLEILMALEIMIDAS N,N''-PUENTEADAS. ADEMAS, SE DESCRIBEN FORMULACIONES FARMACEUTICAS Y METODOS DE UTILIZACION PARA INHIBIR LA PROTEINA QUINASA C EN MAMIFEROS.
ES96308317T 1995-11-20 1996-11-18 Intermedios y su uso para preparar bisindolilmaleimidas con un puente n,n'. Expired - Lifetime ES2145978T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US734595P 1995-11-20 1995-11-20

Publications (1)

Publication Number Publication Date
ES2145978T3 true ES2145978T3 (es) 2000-07-16

Family

ID=21725638

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96308317T Expired - Lifetime ES2145978T3 (es) 1995-11-20 1996-11-18 Intermedios y su uso para preparar bisindolilmaleimidas con un puente n,n'.

Country Status (31)

Country Link
EP (1) EP0776899B1 (es)
JP (2) JP4100708B2 (es)
KR (1) KR100342142B1 (es)
CN (1) CN1066734C (es)
AR (2) AR004718A1 (es)
AT (1) ATE191219T1 (es)
AU (1) AU701659B2 (es)
BR (1) BR9611709A (es)
CA (1) CA2237401C (es)
CO (1) CO4750824A1 (es)
CZ (1) CZ150398A3 (es)
DE (1) DE69607443T2 (es)
DK (1) DK0776899T3 (es)
EA (1) EA000639B1 (es)
ES (1) ES2145978T3 (es)
GR (1) GR3033729T3 (es)
HU (1) HU225716B1 (es)
IL (1) IL124415A (es)
MX (1) MX9803791A (es)
MY (1) MY118946A (es)
NO (1) NO310195B1 (es)
NZ (1) NZ323282A (es)
PE (1) PE17998A1 (es)
PL (1) PL184728B1 (es)
PT (1) PT776899E (es)
TR (1) TR199800876T2 (es)
TW (1) TW371661B (es)
UA (1) UA56145C2 (es)
WO (1) WO1997019080A1 (es)
YU (1) YU49316B (es)
ZA (1) ZA969645B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
AU758241B2 (en) * 1998-03-13 2003-03-20 University Of British Columbia, The Granulatimide derivatives for use in cancer treatment
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6300106B1 (en) 2000-11-22 2001-10-09 Ppg Industries Ohio, Inc. Method of preparing 3-[2-{(Methylsulfonyl)oxy}-ethoxy ]-4-(triphenylmethoxy)-1-butanol, methane sulfonate
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
WO2023192984A1 (en) * 2022-03-31 2023-10-05 4M Therapeutics Inc. N-desmethyl ruboxistaurin as kinase inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
IL94274A0 (en) * 1989-05-05 1991-03-10 Goedecke Ag Maleinimide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same
UA44690C2 (uk) * 1993-12-07 2002-03-15 Елі Ліллі Енд Компані Макроциклічна сполука іміду біс-індол-малеїнової кислоти, спосіб її одержання та фармацевтична композиція, макроциклічні сполуки іміду біс-індол-малеїнової кислоти та біс-індол-малеїнового ангідриду, спосіб одержання (варіанти)
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides

Also Published As

Publication number Publication date
EP0776899A1 (en) 1997-06-04
GR3033729T3 (en) 2000-10-31
YU61096A (sh) 1999-03-04
UA56145C2 (uk) 2003-05-15
AR004719A1 (es) 1999-03-10
IL124415A (en) 2003-11-23
WO1997019080A1 (en) 1997-05-29
PL326753A1 (en) 1998-10-26
YU49316B (sh) 2005-06-10
AU7738896A (en) 1997-06-11
NZ323282A (en) 1999-01-28
JP2000500496A (ja) 2000-01-18
JP2008138006A (ja) 2008-06-19
TR199800876T2 (xx) 1998-08-21
DK0776899T3 (da) 2000-07-10
DE69607443D1 (de) 2000-05-04
CZ150398A3 (cs) 1998-12-16
TW371661B (en) 1999-10-11
HUP9901975A2 (hu) 1999-11-29
AR004718A1 (es) 1999-03-10
MY118946A (en) 2005-02-28
IL124415A0 (en) 1998-12-06
CA2237401C (en) 2003-10-21
CN1207740A (zh) 1999-02-10
NO982105L (no) 1998-05-08
HU225716B1 (en) 2007-07-30
CN1066734C (zh) 2001-06-06
KR100342142B1 (ko) 2002-08-22
CA2237401A1 (en) 1997-05-29
PE17998A1 (es) 1998-04-20
EA000639B1 (ru) 1999-12-29
DE69607443T2 (de) 2000-08-10
EP0776899B1 (en) 2000-03-29
AU701659B2 (en) 1999-02-04
JP4100708B2 (ja) 2008-06-11
ZA969645B (en) 1998-05-18
CO4750824A1 (es) 1999-03-31
EA199800368A1 (ru) 1998-12-24
KR19990067600A (ko) 1999-08-25
PT776899E (pt) 2000-08-31
MX9803791A (es) 1998-09-30
NO310195B1 (no) 2001-06-05
NO982105D0 (no) 1998-05-08
PL184728B1 (pl) 2002-12-31
ATE191219T1 (de) 2000-04-15
BR9611709A (pt) 1999-02-23
HUP9901975A3 (en) 2000-01-28

Similar Documents

Publication Publication Date Title
YU49315B (sh) Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
PT758248E (pt) Formulacoes para o factor ix
ES2162843T3 (es) Inhibidores de la proteina quinasa c.
DE69620877T2 (de) Arzneimittelformulierungen für il-12
TR200001603T2 (tr) Yeni bileşikler
BG103657A (en) New modifications of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminebenzene and methods for their prepration
HN1997000072A (es) Procedimiento para la preparacion de sildenafil
FI972945A (fi) Antigeenien antamiseen soveltuvia koostumuksia
NO970042L (no) 2-£(Dihydro)pyrazolyl-3'-oksymetylen|-anilider, fremgangsmåte til fremstilling og anvendelse derav
ES2170918T3 (es) Inhibidor de proteina quinasa c sustituidos con halo.
IT1293778B1 (it) 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
BR9812773A (pt) "alfa-amino-epsilon-caprolactamas policìclicas e compostos relacionados"
ES2145978T3 (es) Intermedios y su uso para preparar bisindolilmaleimidas con un puente n,n'.
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
FI962481A (fi) 4-bentsoyyli-isokatsolit ja niiden käyttö herbisideinä
DK0696278T3 (da) Herbicidtvirkende substituerede 1-phenyl- eller 1-pyridinylbenzotriazoler
ES2192034T3 (es) Feniluracilos substituidos con efecto herbicida.
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao
TR199900013T2 (xx) Yeni bile�ikler.
DK0418990T3 (da) 13-brom- og 13,14-dibrom-ergoliner, deres fremstilling og anvendelse i lægemidler
FI934468A0 (fi) Bensenborsyraderivat, foerfarande foer deras framstaellning och deras anvaendning som sytesmellanprodukter
ECSP961938A (es) Nuevos intermedios y su uso para preparar bisindolilmaleimidas con un puente n, n-caso x - 10386
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.
ECSP961937A (es) Inhibidor de proteina quinasa "c"
MX9307735A (es) Nuevas triazolopirimidonas, su obtencion y uso.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 776899

Country of ref document: ES